152 related articles for article (PubMed ID: 30891882)
21. Concentration of extracellular vesicles isolated from blood relative to the clinical pathological status of dogs with mast cell tumours.
Šimundić M; Švara T; Štukelj R; Krek JL; Gombač M; Kralj-Iglič V; Tozon N
Vet Comp Oncol; 2019 Dec; 17(4):456-464. PubMed ID: 31066969
[TBL] [Abstract][Full Text] [Related]
22. Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014).
Stefanello D; Buracco P; Sabattini S; Finotello R; Giudice C; Grieco V; Iussich S; Tursi M; Scase T; Di Palma S; Bettini G; Ferrari R; Martano M; Gattino F; Marrington M; Mazzola M; Elisabetta Vasconi M; Annoni M; Marconato L
J Am Vet Med Assoc; 2015 Apr; 246(7):765-9. PubMed ID: 25794126
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of bone marrow aspirates from multiple sites for staging of canine lymphoma and mast cell tumours.
Aubry OA; Spangler EA; Schleis SE; Smith AN
Vet Comp Oncol; 2014 Mar; 12(1):58-66. PubMed ID: 22577893
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours.
Rodriguez S; Fadlalla K; Graham T; Tameru B; Fermin CD; Samuel T
J Comp Pathol; 2012; 147(2-3):171-6. PubMed ID: 22289273
[TBL] [Abstract][Full Text] [Related]
25. HSP32 and HSP90 Immunoexpression, in Relation to Kit Pattern, Grading, and Mitotic Count in Canine Cutaneous Mast Cell Tumors.
Romanucci M; Massimini M; Ciccarelli A; Malatesta D; Bongiovanni L; Gasbarre A; Della Salda L
Vet Pathol; 2017 Mar; 54(2):222-225. PubMed ID: 27627984
[TBL] [Abstract][Full Text] [Related]
26. Canine subcutaneous mast cell tumor: characterization and prognostic indices.
Thompson JJ; Pearl DL; Yager JA; Best SJ; Coomber BL; Foster RA
Vet Pathol; 2011 Jan; 48(1):156-68. PubMed ID: 21078881
[TBL] [Abstract][Full Text] [Related]
27. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs.
Zemke D; Yamini B; Yuzbasiyan-Gurkan V
Vet Pathol; 2002 Sep; 39(5):529-35. PubMed ID: 12243462
[TBL] [Abstract][Full Text] [Related]
28. Proliferative activity of canine mast cell tumours evaluated by bromodeoxyuridine incorporation and Ki-67 expression.
Sakai H; Noda A; Shirai N; Iidaka T; Yanai T; Masegi T; Shirai N; Iidaka T; Yanai T; Masegi T
J Comp Pathol; 2002 Nov; 127(4):233-8. PubMed ID: 12443730
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and risk factors for mast cell tumours in dogs in England.
Shoop SJ; Marlow S; Church DB; English K; McGreevy PD; Stell AJ; Thomson PC; O'Neill DG; Brodbelt DC
Canine Genet Epidemiol; 2015; 2():1. PubMed ID: 26401329
[TBL] [Abstract][Full Text] [Related]
30. Incorporation of sentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures.
Worley DR
Vet Comp Oncol; 2014 Sep; 12(3):215-26. PubMed ID: 22958227
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome for MCTs of canine pinnae treated with surgical excision (2004-2008).
Schwab TM; Popovitch C; DeBiasio J; Goldschmidt M
J Am Anim Hosp Assoc; 2014; 50(3):187-91. PubMed ID: 24659731
[TBL] [Abstract][Full Text] [Related]
32. Identification of additional mitochondrial DNA mutations in canine mast cell tumours.
Śmiech A; Ślaska B; Surdyka M; Grzybowska-Szatkowska L; Łopuszyński W; Różańska D
Acta Vet Scand; 2016 May; 58(1):28. PubMed ID: 27146669
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical application of an antibody specific for human CD1a to the diagnosis of canine mast cell tumour.
Yhee JY; Hong SW; Yu CH; Doster AR; Blas-Machado U; Lyoo YS; Sur JH
J Comp Pathol; 2008 Jul; 139(1):40-6. PubMed ID: 18602642
[TBL] [Abstract][Full Text] [Related]
34. Multivariate survival analysis of histological parameters and clinical presentation in canine cutaneous mast cell tumours.
Preziosi R; Sarli G; Paltrinieri M
Vet Res Commun; 2007 Apr; 31(3):287-96. PubMed ID: 17195927
[TBL] [Abstract][Full Text] [Related]
35. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001).
Sfiligoi G; Rassnick KM; Scarlett JM; Northrup NC; Gieger TL
J Am Vet Med Assoc; 2005 Apr; 226(8):1368-74. PubMed ID: 15844431
[TBL] [Abstract][Full Text] [Related]
36. Cutaneous mast cell tumour within a lipoma in a boxer.
Jakab C; Szász AM; Kulka J; Schaff Z; Rusvai M; Németh T; Gálfi P
Acta Vet Hung; 2009 Jun; 57(2):263-74. PubMed ID: 19584039
[TBL] [Abstract][Full Text] [Related]
37. Is lymph node metastasis of canine grade 2 MCTs justification for adjuvant therapy?
Schulman FY
Vet Comp Oncol; 2015 Jun; 13(2):151. PubMed ID: 25968074
[No Abstract] [Full Text] [Related]
38. The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours.
Costa Casagrande TA; de Oliveira Barros LM; Fukumasu H; Cogliati B; Chaible LM; Dagli ML; Matera JM
Vet Comp Oncol; 2015 Mar; 13(1):1-10. PubMed ID: 23294979
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of P-glycoprotein, STAT3, phospho-STAT3 and KIT in spontaneous canine cutaneous mast cell tumours before and after prednisolone treatment.
Teng SP; Hsu WL; Chiu CY; Wong ML; Chang SC
Vet J; 2012 Aug; 193(2):551-6. PubMed ID: 22398132
[TBL] [Abstract][Full Text] [Related]
40. Widespread mismatch repair protein expression in canine cutaneous mast cell tumors.
Munday JS; French AF; Gibson IR; Gwynne K
Vet Pathol; 2009 Mar; 46(2):227-32. PubMed ID: 19261633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
